Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Caliper Life Sciences Launches Drug Discovery and Development Services Business

Published: Tuesday, January 09, 2007
Last Updated: Tuesday, January 09, 2007
Bookmark and Share
Caliper combines in vitro and in vivo services of Novascreen Biosciences and Xenogen Biosciences to form Discovery Alliances & Services.

Caliper Life Sciences, Inc.,has unveiled Caliper Discovery Alliances & Services (CDAS), the newly-formed services organization created from the integration of NovaScreen Biosciences, a provider of in vitro discovery services, and Xenogen Biosciences, a provider of in vivo discovery services.

NovaScreen was acquired by Caliper in October 2005 and Xenogen was acquired by Caliper in August 2006.

Through these key acquisitions, Caliper has assembled a wide range of in vitro and in vivo products and services that can enable pharmaceutical companies to increase the pace and clinical relevance of drug research.

Caliper's strategy is to provide its customers with the tools for building an "In Vitro-In Vivo Bridge" (I-I Bridge) to address the growing pressure on the pharmaceutical industry to find drugs while minimizing the risk of adverse effects of those drugs.

"The launch of CDAS is one in a series of practical solutions that Caliper is offering the pharmaceutical industry, with the goal of reducing attrition of drug candidates as they move from in vitro to in vivo experiments," said Kevin Hrusovsky, president and CEO of Caliper.

"By building the I-I Bridge in the context of a services offering, we are providing scientists a way to explore new approaches to drug discovery with minimal resource commitment."

According to Caliper its Discovery Alliances & Services can offer more than 700 in vitro assay types, including receptor, enzyme, and ion channel screening and profiling assays, side effect and ADME-tox panels, and cellular models for immunology, oncology, and other fields.

In vivo offerings include more than 85 pharmacological assays that measure over 400 different parameters for applications such as in vivo compound profiling and phenotyping, and target validation studies.

Other in vivo services include creation of genetically modified animal models and biophotonic imaging-based animal models for oncology and other therapeutic areas.

Immunology research is one therapeutic area where CDAS can offer assays that span the I-I Bridge.

"The demand for outsourced drug discovery services is growing rapidly as companies increasingly recognize the critical need for comprehensive characterization of potential safety or side effect liabilities of their drug candidates," said David Manyak, executive vice president of discovery services of Caliper Life Sciences and head of CDAS.

"We are excited to now be one of the few providers focused on offering services that span in vitro and in vivo experimentation, and look forward to working in partnership with our customers to help them bring safe and effective new drugs to market."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Caliper LS Receives $1.1 Million Task Order from the EPA's ToxCast™ Screening Program
This task order was issued pursuant to a contract that Caliper was awarded by the EPA in April 2007 under the ToxCast program.
Wednesday, August 20, 2008
Caliper Life Sciences Forms Alliance with Horizon Discovery
CDAS expands offering to include screening for targeted cancer drugs using genetically-defined in-vitro human disease models.
Thursday, April 10, 2008
Caliper Life Sciences Awarded EPA Contract
Caliper Discovery Alliances and Services unit will test environmental chemicals under EPA’s ToxCast research program.
Tuesday, April 10, 2007
Caliper Strengthens Distribution Channels in China, Hong Kong and India
Leading international distributors expand customer access to Caliper microfluidics and drug discovery technologies.
Monday, February 13, 2006
Caliper Completes Acquisition of NovaScreen
The acquisition combines NovaScreen's screening, profiling and assay development services with Caliper's LabChip® and liquid handling products.
Thursday, October 06, 2005
Caliper Technologies expands Caliper 250 system

Monday, March 10, 2003
Caliper cut's Amphora Discovery's purchase obligations

Tuesday, December 17, 2002
Zymark Supplies HTS Systems to Vertex Pharmaceuticals

Tuesday, October 15, 2002
Scientific News
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
HIV Susceptibility Linked to Little-Understood Immune Cell Class
High levels of diversity among immune cells called natural killer cells may strongly predispose people to infection by HIV, and may be driven by prior viral exposures, according to a new study.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
Long-sought Discovery Fills in Missing Details of Cell 'Switchboard'
A biomedical breakthrough reveals never-before-seen details of the human body’s cellular switchboard that regulates sensory and hormonal responses.
Tracking Breast Cancer Before it Grows
A team of scientists led by University of Saskatchewan researcher Saroj Kumar is using cutting-edge Canadian Light Source techniques to screen and treat breast cancer at its earliest changes.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
DNA Damage Seen in Patients Undergoing CT Scanning
Along with the burgeoning use of advanced medical imaging tests over the past decade have come rising public health concerns about possible links between low-dose radiation and cancer.
The Light of Fireflies for Medical Diagnostics
EPFL scientists have exploited the light of fireflies in a new method that detects biological molecules without the need for complex devices and high costs.
Vital Protein in Healthy Fertilization Process Identified
Researchers at the National Institutes of Health have discovered a protein that plays a vital role in healthy egg-sperm union in mice.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!